Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Gynecologic 1CNS 1

Conditions

Glioblastoma 405Brain Neoplasms 163Glioma 159Gliosarcoma 128Astrocytoma 115Central Nervous System Neoplasms 110Oligodendroglioma 74Neuroblastoma 44Medulloblastoma 33Ependymoma 26Recurrence 23Neoplasms 19Neoplasm Metastasis 16Diffuse Intrinsic Pontine Glioma 15Choroid Plexus Neoplasms 13Optic Nerve Glioma 11Melanoma 11Spinal Cord Neoplasms 10Rhabdoid Tumor 10Lymphoma 9Familial ependymoma 9Rhabdomyosarcoma 8Osteosarcoma 8Neuroectodermal Tumors, Primitive 8Breast Neoplasms 8Sarcoma, Ewing 6Sarcoma 6Pinealoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Glioma, Subependymal 6

Interventions

silmitasertib 1sargramostim 1Vincristine 1Trabectedin 1Temozolomide 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Irinotecan 1Immunotherapy 1Drug Therapy 1Cyproheptadine 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liposarcoma × Temozolomide × CNS × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡